

PT SARATOGA INVESTAMA SEDAYA TBK

FY16 and 1Q17 results May 2017

Disclaimer



"These materials have been prepared by PT Saratoga Investama Sedaya, Tbk (the "Company") from various internal sources and have not been independently verified. These materials are for information purposes only and do not constitute or form part of an offer, solicitation or invitation of any offer to buy or subscribe for any securities of the Company, in any jurisdiction, nor should it or any part of it form the basis of, or be relied upon in any connection with, any contract, commitment or investment decision whatsoever. Any decision to purchase or subscribe for any securities of the Company should be made after seeking appropriate professional advice.

These materials contain embedded statements that constitute forward-looking statements. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the consolidated results of operations and financial condition of the Company. These statements can be recognized by the use of words whether or not explicitly stated such as "expects," "plan," "will," "estimates," "projects," "intends," or words of similar meaning. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors and assumptions. The Company has no obligation and does not undertake to revise forward-looking statements to reflect future events or circumstances.

No representation or warranty, expressed or implied, is made and no reliance should be placed on the accuracy, fairness or completeness of the information presented or contained in these materials. The Company or any of its affiliates, advisers or representatives accepts no liability whatsoever for any loss howsoever with respect to any use or reliance upon any of the information presented or contained in these materials. The information presented or contained in these materials. The information presented or contained in these materials.



CORPORATE INFORMATION

Saratoga – A Leading Active Investment Company

SARATOGA

- Leading active investment company in Indonesia with NAV of c.US\$1.5 billion
- Listed in 2013 and is among the top 100 largest market capitalization stocks on the IDX
- Focused on early-stage, growth-stage, and special situation opportunities
- Actively engaged with investee companies' management teams in unlocking value of investments
- Invested in key sectors of the Indonesian economy: Consumer, Infrastructure and Natural Resources



Diversified Investment Portfolio



We invest across the three key sectors in early and growth stages with the goal of creating listed blue chip companies

blue chip companies	Early Stage Companies	Growth Companies	Listed Blue Chip Companies	
SARATOGA	 Early-stage companies provide large upside potential Ability to acquire larger stakes allows SIS to exert significant influence, develop company strategy and products and generate strong return 	 Growth companies generate sustainable and healthy cash flows for SIS' portfolio Provides great upside potential when growth companies enter into mature phases 	 Blue-chip Investee Companies are established industry leaders with growth and capital appreciation opportunities SIS to remain a long-term shareholder in these businesses 	% Sum of the Parts (SOTP)
Natural Resources	Sihayo Copper GoldGoldSumatra Copper & GoldGoldFinders ResourcesCopperAgro Maju RayaPalmAgra Energi IndonesiaOil & Gas	Merdeka Copper Gold Gold & Copper Provident Agro Palm Interra Resources Oil & Gas	Adaro Energy Coal & Power	52%
Infrastructure	Tenaga Listrik Gorontalo Power	Medco Power IndonesiaPowerPaiton EnergyPowerTri Wahana UniversalRefineryNusa Raya CiptaConstructionSeroja InvestmentShippingSinar Mentari PrimaShipping	Tower Bersama Infrastructure <i>Telco Tower</i>	38%
Consume		Mitra Pinasthika MustikaAutoGilang Agung PersadaLifestyleEtika Karya UsahaPropertyMulia Bosco LogistikLogisticsAwal Bros HospitalHealthcareDeltomedHerbal Medicine		10%
SOTP	2%	27%	71%	


Listed investment companies in bold Data presented are as of 31 March 2017 IDR/USD as of 31 March 2017 = 13,321 Source: Company information

∠/ /0

71%

Net Asset Value per Share Growth

Saratoga has maintained a consistent track record of increasing net asset value and outperforming the Jakarta Composite Index



SARATOGA

(1) NAV per Share is adjusted on capital raising. The information contained in this document is intended solely for the use of our internal reference. We make no representations or warranties, express or implied, with respect to the information herein.


(2) For NAV per Share between 2008 and 2014, valuation of listed investee companies are calculated based on 2W VWAP as of year end close. Due to the implementation of new accounting standards in 2016, the 2015 and 2016 calculations for listed investee companies are based on their respective closing share price as of 31 December 2016

Data presented are as of 31 March 2017 Source: Company information

Figures in IDR

$\textbf{Invest} \rightarrow \textbf{Grow} \rightarrow \textbf{Monetize Investment Approach}$





Data presented are as of 31 Dec 2016 IDR/USD as of 31 Dec 2016 = 13,436 Source: Company information




INVESTMENT ACTIVITIES

Investment Opportunity Selection



Despite market conditions, we select new investments in a **disciplined and prudent approach**. We consistently managed to gather 100+ opportunities and **executed 2-3 new investments annually**



Investments and Divestments in Q117



We increased our overall exposure to the consumer sector and plan to continue growing our exposure in this space

	New investments	Divestments
	delto med	CARS -
Investment details	Date of Investment: March 2016 Invested Capital: IDR 85.75 billion	Date of Investment: 2006 Sale proceeds: IDR900 billion
Investment / divestment thesis	 Leading player in herbal remedy industry Established brand equity. Scalability and ample growth opportunity through increasing healthy living trends and growing middle income. 	A long term investment project since 2006. As the toll-road has been built and the operation has commenced the firm decide to divest and deploy capital elsewhere.
Company description	 Deltomed is one of the leading herbal remedy players in Indonesia. Deltomed's product, Antangin, is the second largest herbal wind flu remedy brand by market share, while OB Herbal is the market leader for herbal cough medicine in Indonesia. Uniquely positioned as one of the few producers with vertically integrated operations and strong distribution network. 	LMS is an infrastructure company established in 2005 to construct and operate a 116 kilometer toll road that will connect Cikampek and Palimanan in West Java and that will eventually become part of the Trans Java Toll Road network.

Investments and Divestments in 2016




We increased our overall exposure to the consumer sector and plan to continue growing our exposure in this space

	New investments		Divestments	
	MGM BOSCO	RS AWAL BROS Hospital Group	Pulau Seroja Jaya	Other notable divestments
Investment details	Date of Investment: January 2016 Invested capital: IDR32 billion	Date of Investment: October 2016 Invested capital: IDR75 billion	Date of Investment: 2008 Sale proceeds: IDR98 billion	Palm plantation assets owned by Provident
Investment / divestment thesis	 High demand on vital logistics infrastructure Scalable business Reputable brand Limited players in the segment 	 High growth prospects Relatively defensive nature of business Scalability Leading quality healthcare provider 	Unwinding exposure in the shipping industry due to the slowdown of the underlying sector and global economy.	Agro at a market premium price per hectare
Company description	 Provides refrigerated trucking service serving FMCG blue-chip clients, connecting over 20 cities and operates cold storage facilities in North Jakarta MBL aims to scale up its business to deliver end-to-end cold chain logistics benefits for its clients 	 Hospital group that operates 9 hospitals in Jakarta, Bekasi, Tangerang, Pekanbaru, Batam and Makasar under the Awal Bros brand Largest hospital operator for BPJS, Indonesia's Social Security Organising Body 	Provides services include freight charters for shipments of dry bulk goods, thermal coal, sand and other mineral resources.	

Investments and Divestments



2016 has proven to be a successful year based on the invest-grow-monetize business model we have set out to achieve





FINANCIAL HIGHLIGHTS

Highlights of Q1' 2017

Total liabilities

Equity attributable to shareholders

Consolidated Statement of Profit and Loss (IDR millions)	Q1 2017	Q1 2016	% variance
Income	858,477	3,254,756	(73.6%)
Expenses	(115,550)	(121,614)	(5.0%)
Profit before tax	742,927	3,133,142	(76.3%)
Income tax	28,038	224	nm
Profit for the period	770,965	3,133,366	(75.4%)
Attributable to owners of the company	873,859	2,935,673	(70.2%)
Attributable to non-controlling interests	(102,894)	197,693	nm
Other comprehensive income	499,589	(1,247,369)	nm
Total comprehensive income for the period	1,270,554	1,885,997	(32.6%)
Attributable to owners of the company	1,333,693	1,716,658	(22.3%)
Attributable to non-controlling interests	(63,139)	169,339	(137.3%)
Key Balance Sheet Items (IDR millions)	Mar 2017	Dec 2016	% variance
Investment in equity securities	24,181,966	23,801,617	1.6%
Cash and cash balances	1,167,532	488,439	139.0%
Borrowings	4,523,743	4,574,832	(1.1%)

5.418.105

20,462,877

5,777,735

18,984,334

(6.2%)

7.8%



Key highlights:

Q1'17 performance mainly driven by the share price movement of listed investee companies:

Increase in share price and contribution to

- TBIG (IDR4,980 to IDR5,450): IDR760 billion
- ADRO (IDR1,695 to IDR1,750): IDR284 billion
- MDKA (IDR2,000 to IDR 2,500): IDR340 billion

Decrease in share price

 PALM (IDR 456 to IDR 400) which has adversely impacted our value by IDR176 billion

Divestment

 Completed the sale of PT Lintas Marga Sedaya – operator of Cipali toll-road on 17 January 2017

Key variances:

Decrease in income

 The decrease in income was due to first implementation implication on SFAS 65 (IFRS 10) – on investment entity.

Increase in income tax

Reversal on deferred tax, as a result on sale of investment
 asset

Increase in other comprehensive income

• Due to mark to market from AFS portfolio, majorly coming from Adaro shares.

Key Financial Statement – FY2016



Figures in IDR billion

Profit & Loss Statement	
Unrealized net gain on investment in equity securities ⁽¹⁾	6,344
Dividend Income	622
Net gain on FX differences	91
Other income	422
Total Income	7,478
Interest Cost	(283)
Operating Expenses (incl. Salary)	(144)
Other Costs	(467)
Total Expenses	(893)
Profit for the period attributable to shareholders	5,670


Statement of Financial Position	
Cash and cash equivalents	488
Restricted cash	270
Investment in equity securities	23,802
Advances for investment in equity securities	69
Others	515
Total Assets	25,144
Borrowings	2,792
Medium Term Notes	721
Exchangeable Bond	1,062
Deferred Tax	847
Others	356
Total Liabilities	5,778
Net Equity attributable to shareholders	18,985
Net Asset Value of investment portfolio ⁽²⁾	19,540

(1) Includes one-off gain of IDR3,395 billion due to the change in financial reporting(2) NAV accounted exchangeable bond on a cash basis instead of fair value

Diversified Sources of Cash and Liquidity




Record amount of dividends in 2016 and highest since Saratoga became a listed company in 2013



Data presented are as of Dec 2016, unless specified otherwise IDR/USD as of 31 Dec 2016 = 13,436 Source: Company information

Strong Capital Structure Backed by Diverse Funding Sources





Total borrowings as of 31 March 2017 stands at US\$343 million

Data presented are as of March 2017, unless specified otherwise IDR/USD as of 31 March 2017 = 13,321 Source: Company information

Funding sources

Continue to tap diverse funding sources whilst managing cost effective and conservative leverage is a key part of our active investment operating model

Bank Loans

- Types: Revolving Credit Facility, Bilateral Loan
- Banks: SCB, ING, Natixis, and HSBC

Medium Term Notes

- Issued a 3-year IDR 725 billion MTN in October 2014 with a fixed rate of 11.75%
- Offered under private placement
- Arranger: DBS Vickers

Exchangeable Bond

- Issued a 5-year, put option at year 3, US\$100 million EB in May 2015 with a coupon of 3%, YTM 3.75%
- Exchangeable to TBIG common shares at IDR 10,707

Cash Availability:

- Preserve Cash at Saratoga's parent level sufficient to cover our borrowing principal
- · Keep Bank facility available for immediate needs

Operating Expense vs. NAV



(In IDR billion)

Cost ratio & Coverage ratio	Opex/NAV	Opex + Interest/N AV	Dividend/ Interest	Dividend/ Interest + Opex.
2013	0.61%	1.73%	1.1x	0.7x
2014	0.45%	1.43%	1.2x	0.8x
2015	1.03%	2.81%	1.1x	0.6x
2016	0.74%	2.18%	2.19x	1.4x

Operating Expense

- We maintain low operating expense at parent level below 1%.
- Operating Expense includes salary, rental, professional fees, and other operating expenses at Saratoga parent level.
- The increase in OpEx/NAV ratio in 2015 was driven by both the decline in NAV and increase OpEx related to investment due diligence activities and EB issuance.

Change to Financial Reporting Presentation



Starting from the first half of 2016, we began to apply "PSAK 65: Exemption on the Consolidation" in reporting our financial performance, which is aligned with the Company's business model as an active investment company, provides more transparency to daily business activities and reflects the true value growth of the Company

As the change is applied prospectively, the Company's 2016 financial reports is not comparable with its 2015 financial reports

Key accounting changes	Financial reports prior to 2016	Financial reports from 2016 onwards
Operating subsidiaries	Consolidated into accounts	 Not consolidated except for subsidiaries that are considered an extension of the Company's investing activities i.e. provide investment management services
Investments in controlled entities, associates and joint ventures (with ownership of ≥20%)	Accounted at equity value	 Accounted as fair value to profit and loss New account of "Unrealized Net Gain on Investment in Equity Securities" to reflect unrealized potential gain
Investments classified as Available for Sale (with ownership of <20%)	 Accounted as mark-to-market to Other Comprehensive Income account 	 Accounted as mark-to-market to Other Comprehensive Income account



For further information, please contact: Investor Relations at <u>Investor.relations@Saratoga-investama.com</u>